Compare DraftKings Inc (DKNG) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DraftKings Inc vs Gilead Sciences, Inc. — how do they compare? DraftKings Inc trades at $25.33 (market cap $12.05B), while Gilead Sciences, Inc. trades at $135.89 (market cap $164.99B). The key difference: Gilead Sciences, Inc. is far larger — about 13.7× DraftKings Inc's market cap, and Gilead Sciences, Inc. pays a 2.47% dividend while DraftKings Inc pays none. Which is the better fit depends on your goals.
| DKNG | GILD | |
|---|---|---|
Market Cap | $12.05B | $164.99B |
Sector | Consumer Cyclical | Health |
52-Week High | $48.23 | $155.80 |
52-Week Low | $20.72 | $110.56 |
Enterprise Value | $12.98B | $188.06B |
Dividend Yield | — | 2.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DraftKings (DKNG) trades at $24.03, up 8.39% today, but remains under pressure with a bearish technical signal. Recent Q2 2026 earnings missed expectations, with an EPS loss of $0.14 versus a $0.02 profit forecast. Revenue grew to $6.05 billion in 2025, but net income margins are negative. Analyst consensus is bullish with a $33.86 price target, though news highlights competition from prediction markets and promotional costs.
The outlook is mixed: strong revenue growth and positive operating cash flow support long-term potential, but profitability challenges and competitive threats pose risks. Upside depends on execution in new markets and cost management, while investor sentiment is cautious amid recent earnings misses and bearish technical trends.
Gilead Sciences (GILD) trades at $133.21, up 1.8% in the last session, with a bullish technical outlook and strong analyst support. Recent Q2 2026 results showed a revenue beat despite a net loss driven by acquisition costs, with HIV drug sales and pipeline progress fueling raised full-year guidance. The stock exhibits robust cash flow from operations and a high gross margin, though negative net income and elevated debt levels present fundamental concerns.
The outlook is positive based on raised sales guidance and pipeline momentum, but risks include patent cliffs for key HIV drugs by the mid-2030s and integration challenges from recent acquisitions. With a consensus price target of $151.22 implying 13.5% upside, Wall Street sentiment is bullish, though investors should weigh growth prospects against execution and regulatory risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DraftKings Inc
DraftKings Inc is a digital sports entertainment and gaming company. The company provides users with daily fantasy sports (DFS), sports betting, and iGaming opportunities and is also involved in the design & development of sports betting and casino gaming platform software for online and retail sportsbook and casino gaming products. It operates in two segments: Business-to-consumer(B2C) and Business-to-Business(B2B), of which the vast majority of its revenue comes from the B2C segment. Geographically, it derives most of its revenue from the United States.
Read more on DKNG →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
